Dr Reddy's Laboratories announces the launch of Febuxostat Tablets in the US Market
Hyderabad, India and Princeton, NJ, USA. January 11, 2021: Dr. Reddy’s Laboratories Ltd. ((BSE: 500124, NSE: DR REDDY, NYSE: RDY, NSEIFSC: DR REDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Febuxostat Tablets, a therapeutic equivalent generic version of Uloric (Febuxostat) Tablets approved by the U.S. Food and Drug Administration (USFDA).
The Uloric brand and generic had U.S. sales of approximately $108 million MAT for the most recent twelve months ending in October 2020 according to IQVIA Health*.
Dr. Reddy’s Febuxostat Tablets are available in 40 mg and 80 mg strengths in bottle count sizes of 30 tablets.
Please see the full prescribing information including boxed warning.
The Uloric brand and generic had U.S. sales of approximately $108 million MAT for the most recent twelve months ending in October 2020 according to IQVIA Health*.
Dr. Reddy’s Febuxostat Tablets are available in 40 mg and 80 mg strengths in bottle count sizes of 30 tablets.
Please see the full prescribing information including boxed warning.